Table 3.
n (%) of positive patients | All n = 42 | LN+ n = 20 (47.6%) | LN- n = 22 (52.4%) | Wilcoxon P value | |
---|---|---|---|---|---|
GM.CSF | 4 (10%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.051 |
IFN-γ | 6 (14%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.444 |
IL-1β | 7 (7%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.632 |
IL-2 | 21 (50%) | 42 (0; 133) | 0 (0; 151) | 83 (0; 119) | 0.851 |
IL-4 | 2 (2%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.365 |
IL-5 | 19 (19%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.440 |
IL-6 | 41 (98%) | 1241 (503; 1,544) | 1324 (764; 1,496) | 1093 (258; 1,720) | 0.462 |
IL-10 | 22 (52%) | 4 (0; 13) | 4.4 (0; 12) | 0 (0; 14) | 0.926 |
IL-12p70 | 0 | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | NA |
IL-13 | 4 (10%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.348 |
IL-15 | 38 (91%) | 114 (47; 197) | 180 (109; 261) | 62 (23; 115) | 0.002 |
IL-17 | 11 26%) | 0 (0; 20) | 0 (0; 7) | 0 (0; 26) | 0.757 |
IL-17F | 12 (29%) | 0 (0; 12) | 0 (0; 6) | 0 (0; 12) | 0.728 |
IL-21 | 19 (45%) | 0 (0; 817) | 0 (0; 773) | 0 (0; 958) | 0.591 |
IL-22 | 1 (2%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.317 |
IL-23 | 15 (36%) | 0 (0; 212) | 0 (0; 190) | 0 (0; 262) | 0.758 |
IL-28A | 0 | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | NA |
CCL20 | 34 (81%) | 37 (6; 497) | 23 (7; 284) | 40 (1; 624) | 0.752 |
TGF-β1 | 8 (19%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 446) | 0.157 |
TNF-α | 4 (10%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.323 |
TNF-β | 7 (17%) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0.684 |
Data are expressed as median (IQR). NA, not applicable.